Related Experiment Videos
Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis
Liana Tsenova1, Bande Mangaliso, George Muller
1Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021, USA.
Abstract:
Tuberculous meningitis (TBM), the most severe form of Mycobacterium tuberculosis infection in humans, is associated with significant morbidity and mortality despite successful treatment with antituberculous drugs. This is due to the irreversible brain damage subsequent to the local inflammatory response of the host to M. tuberculosis. Corticosteroids have been used in conjunction with antituberculous therapy in an attempt to modulate the inflammatory response, but this strategy has been of limited success. Therefore, we examined whether combining antituberculous drugs with the immunomodulatory drug thalidomide or with a new thalidomide analog, immunomodulatory drug 3 (IMiD3), would be effective in reducing morbidity and mortality in an experimental rabbit model of TBM. Intracisternal inoculation of 5 x 10(4) CFU of Mycobacterium bovis Ravenel in rabbits induced progressive subacute meningitis characterized by high cerebrospinal fluid (CSF) leukocytosis, protein influx, release of tumor necrosis factor (TNF), substantial meningeal inflammation, and mortality by day 28. Treatment with antituberculous drugs or with antituberculous drugs plus thalidomide improved the clinical course of disease somewhat and increased survival to about 50%. In contrast, treatment with antituberculous drugs in combination with IMiD3 limited pathological neurologic changes and resulted in marked improvement (73%) in survival. IMiD3 treatment was also associated with reduced leukocytosis in the CSF and significantly lower levels of TNF in CSF and plasma. Histologically, the meningeal inflammation in animals treated with antituberculous drugs plus IMiD3 was considerably attenuated compared to that of the other treatment groups. These results suggest a potential role for IMiD3 in the management of TBM in patients.
Insights
New immunomodulatory drug 3 (IMiD3) combined with antitubercular drugs significantly improved survival in a tuberculous meningitis (TBM) rabbit model. IMiD3 reduced inflammation and neurological damage, offering potential for TBM patient management.
Area of Science:
- Neuroscience
- Immunology
- Infectious Diseases
Background:
- Tuberculous meningitis (TBM) causes severe neurological damage and mortality despite antitubercular drugs.
- Host inflammatory response to Mycobacterium tuberculosis contributes to irreversible brain damage.
- Corticosteroids offer limited success in modulating TBM inflammation.
Purpose of the Study:
- To evaluate the efficacy of combining antitubercular drugs with thalidomide or immunomodulatory drug 3 (IMiD3) in an experimental TBM rabbit model.
- To assess the impact of IMiD3 on morbidity, mortality, and neurological pathology in TBM.
Main Methods:
- Rabbits were intracisternally inoculated with Mycobacterium bovis Ravenel to induce TBM.
- Animals were treated with antitubercular drugs alone, with thalidomide, or with IMiD3.
- Cerebrospinal fluid (CSF) and plasma analyses measured leukocytosis and tumor necrosis factor (TNF) levels.
- Neuropathological changes and survival rates were assessed.
Main Results:
- Antitubercular drugs alone or with thalidomide increased survival to approximately 50%.
- Combination therapy with antitubercular drugs and IMiD3 significantly improved survival to 73%.
- IMiD3 treatment markedly reduced CSF leukocytosis, TNF levels, and meningeal inflammation, limiting neurological damage.
Conclusions:
- IMiD3 demonstrates significant therapeutic potential in reducing TBM-associated inflammation and improving survival.
- Combining IMiD3 with standard antitubercular therapy may offer a more effective strategy for managing tuberculous meningitis.
- Further investigation into IMiD3 for TBM patient management is warranted.